Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.46 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13449767 | 0.84 | KDM4E (0.41) | L3MBTL1MAPTTDP1SMN1; SMN2 | |
| SCHEMBL13050345 | 0.84 | ALDH1A1 (0.45) | L3MBTL1TDP1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL19139302 | 0.84 | MCHR1 (0.47) | L3MBTL1MAPTTDP1SSTR4SSTR1 | |
| SCHEMBL16252788 | 0.84 | L3MBTL1 (0.46) | L3MBTL1MAPTTDP1SSTR4SSTR1 | |
| SCHEMBL10202948 | 0.80 | L3MBTL1 (0.54) | L3MBTL1MAPTTDP1SSTR4KCNH2 | |
| SCHEMBL2354995 | 0.79 | PIM1 (0.36) | L3MBTL1MAPTTDP1SSTR4SSTR1 | |
| SCHEMBL16744336 | 0.79 | PIM1 (0.36) | L3MBTL1MAPTSSTR4SSTR1KCNH2 | |
| SCHEMBL10202961 | 0.79 | L3MBTL1 (0.56) | L3MBTL1MAPTTDP1KCNH2HPGD | |
| SCHEMBL21748887 | 0.78 | SSTR4 (0.55) | SSTR4SSTR1HPGDNPC1RAB9A | |
| SCHEMBL16252759 | 0.77 | HPGD (0.45) | L3MBTL1MAPTTDP1SSTR4SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623898-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-8623898-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| CN-102361845-A | Method for producing conjugated aromatic compound | SUMITOMO CHEMICAL CO | 2012-02-22 | — | — | CN | disclosed |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20100292289-A1 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | AMPLA PHARMACEUTICALS INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20080262226-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | ARTESIAN THERAPEUTICS, INC. (CA) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | SLC18A2, SLC1A2, SLC6A1 | L3MBTL1 2390/4885MAPT 287/4885TDP1 1612/4885 |
| US-20080262226-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | ADRB2, ADRB3, ADRB1 | L3MBTL1 3584/4885MAPT 4285/4885TDP1 1223/4885 |
| US-20100292289-A1 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | GPR119, CPT1A, GLS2 | L3MBTL1 4242/4885MAPT 3155/4885TDP1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.